Terapia alvo de BAFF/APRIL para lúpus eritematoso sistêmico e nefrite lúpica: revisão sistemática e meta-análise
ReumatologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Clinical rheumatology
- Publicado em
- 2 set 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
BAFF/APRIL-targeted therapy for systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis
Lei Jin, Shan-Shan Shi
Descritores MeSH
- Lupus Erythematosus, Systemic
- B-Cell Activating Factor
- Tumor Necrosis Factor Ligand Superfamily Member 13
- Lupus Nephritis
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
- Treatment Outcome
- Humans
Veja também
Estudos relacionados
- Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data
- Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials
- Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis
- Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: A systematic review
- Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis
- Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis